[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499007":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":24,"locations":35,"responsibleParty":56,"collaborators":18,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":18,"enrollmentInfo":69,"targetDuration":18,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University Hospital, Essen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Medication management app","EXPERIMENTAL","Standard of care (statin prescription, targeted monitoring of individual LDL-C values by primary care physician) + medication management app and follow-up visits at our institution at 6 and 18 months",[13],"Other: Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard of care","NO_INTERVENTION","Statin prescription, targeted monitoring of individual LDL-C values by primary care physician and follow-up visits at our institution at 6 and 18 months",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)","Free access to a study version of the medication management app mediteo m+ for reminders and documentation of statin therapy in addition to usual care",[9],[25,31],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Benedikt Frank, PD Dr.","CONTACT","+49 201","723-6546","benedikt.frank@uk-essen.de",{"name":32,"role":27,"phone":28,"phoneExt":33,"email":34},"Amir A Mahabadi, Prof. Dr.","723-4848","Amir-Abbas.Mahabadi@uk-essen.de",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Essen","North Rhine-Westphalia","45147","Germany","DE",{"type":44,"coordinates":45},"Point",[46,47],7.01228,51.45657,{"lat":47,"lon":46},[50,51,53],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},{"name":26,"role":52,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"name":54,"role":55,"phone":18,"phoneExt":18,"email":18},"Amir A Mahabadi, Prof Dr.","SUB_INVESTIGATOR",{"type":52,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Benedikt Frank","Assistant Professor (PD) Dr. med","100499007","improving-adherence-to-statin-therapy-through-a-medication-management-application-100499007",false,"NCT05777655","Improving Adherence to Statin Therapy Through a Medication Management Application","Improving Adherence to Statin Therapy Through a Medication Management Application (STAPP)","STAPP","Inclusion Criteria:\n\n* Age \\>18 years\n* Atherosclerosis (neurovascular, cardiac or peripheral) with an indication to start a high intensity statin-therapy (equivalent to 40mg of atorvastatin or 20mg of rosuvastatin; start of statin therapy +\u002F- 10 days of enrolment)\n* Statin naivety\n* LDL-C \\>100 mg\u002Fdl. No older than 21 days\n\nExclusion Criteria:\n\n* Inability to take medication independently or to use the mediteo m+ app independently (e.g. people in need of care, people with dementia)\n* Patient has no own smartphone (no device provided for this study)\n* Prior drug therapy to lower LDL-C within the last 30 days\n* Active cancer (defined as a diagnosis of cancer within 6 months before enrolment, any treatment for cancer within the previous 6 months, or recurrent or metastatic cancer) or other severe concomitant disease with a life expectancy of \\\u003C6 months\n* Use of a digital therapy management application (including mediteo or mediteo m+) within the last month\n* Participation in another interventional trial\n* Pregnancy\n* Inability or unwillingness to provide informed consent","ALL","18 Years",{"count":70,"type":71},250,"ESTIMATED","INTERVENTIONAL",[74],"NA","Interventional study to compare standard of care vs standard of care plus the use of a medication therapy management smartphone app (mediteo m+, Mediteo GmbH, Heidelberg) in patients with atherosclerotic cardiovascular disease and indication to start high intensity statin therapy.",[77],"Atherosclerosis",[79,80],"Smartphone Application","Medication Therapy Management","2026-04-28",{"date":83,"type":84},"2026-05-04","ACTUAL",{"date":86,"type":84},"2023-02-17",{"date":88,"type":71},"2028-11-28",{"name":5,"class":6},1]